SELLAS Life Sciences Group, Inc. (SLS): Business Model Canvas [Apr-2026 Updated]

You're looking at SELLAS Life Sciences Group, Inc. (SLS) right now, and honestly, the next few months are everything, given the anticipated year-end 2025 readout for the Phase 3 REGAL trial on their lead asset, Galinpepimut-S (GPS). As an analyst who's seen countless clinical-stage biotechs pivot on a single data point, I see a company that's currently funding this critical push with a war chest of about $44.3 million in cash, significantly buttressed by $54.6 million in gross proceeds from recent warrant exercises in September/October 2025. Their value proposition rests on novel mechanisms for high-unmet-need Acute Myeloid Leukemia (AML), but their cost structure-with Q3 2025 R&D at $4.2 million and G&A at $2.9 million-means the clock is ticking toward that pivotal moment. Dive into the full Business Model Canvas below to see exactly how their key resources and partnerships are aligned to deliver on these near-term, event-driven opportunities.

SELLAS Life Sciences Group, Inc. (SLS) - Canvas Business Model: Key Partnerships

You're looking at the network of external entities that help SELLAS Life Sciences Group, Inc. execute its strategy, especially around its two lead assets, GPS and SLS009. These relationships are critical for development, clinical execution, and future commercial reach.

Licensing and Development Partners

The foundation of the pipeline relies on key intellectual property partnerships. SELLAS Life Sciences Group, Inc.'s lead product candidate, GPS, is licensed directly from Memorial Sloan Kettering Cancer Center (MSKCC), which targets the WT1 protein. Furthermore, an Investigator-Sponsored Trial (IST) is actively being conducted with GPS in combination with nivolumab at MSKCC for patients with malignant pleural mesothelioma (MPM).

For SLS009 (tambiciclib), the Company has a critical external relationship with GenFleet Therapeutics (Shanghai) Inc., established in March 2022. This agreement grants SELLAS Life Sciences Group, Inc. exclusive rights for the development and commercialization of SLS009 outside of the Greater China territory. To be fair, the clinical study of SLS009 being conducted in China is fully funded by GenFleet Therapeutics.

Here's a quick look at the core licensing agreements:

Clinical Trial Management and Investigators

The pivotal Phase 3 REGAL trial for GPS requires a robust network of clinical management and expert investigators. The study completed enrollment in April 2024, randomizing a total of 126 patients. The trial execution is managed through a network of Clinical Research Organizations (CROs), with the U.S.-based sites representing the highest enrolling country, and U.S. and European sites accounting for approximately 75% of enrolled patients.

Key Opinion Leaders (KOLs) and investigators are central to the trial's success and data interpretation. SELLAS Life Sciences Group, Inc. hosted a Virtual R&D Day on October 29, 2025, specifically to feature KOLs discussing the programs.

• Dr. Omer Jamy at the University of Alabama (UAB) serves as the principal investigator for the Phase 3 REGAL study at UAB, noted as one of the trial's highest enrolling sites.
• Dr. Panagiotis Tsirigotis at the National and Kapodistrian University of Athens is an investigator in the Phase 3 REGAL trial and has enrolled the highest number of patients in the study.

The trial reached a significant milestone when the Independent Data Monitoring Committee (IDMC) recommended continuation without modification following an interim analysis triggered by 60 events (deaths) in January 2025. The final analysis is planned upon reaching 80 events.

Financial and Strategic Advisors

While specific 2025 commercialization partnership exploration with investment banks like Stifel isn't explicitly detailed in the latest updates, the Company's financial activities show reliance on capital markets and placement agents to fund operations, which often precedes or supports commercial structuring. As of September 30, 2025, the cash and cash equivalents position stood at approximately $44.3 million. This was bolstered by receiving $29.1 million in net proceeds from warrant exercises in October 2025.

Earlier in 2025, a registered direct offering on or about January 29, 2025, generated gross proceeds expected to be approximately $25 million at a combined purchase price of $1.27 per share and accompanying warrant. Maxim Group LLC acted as a placement agent for this offering.

These financial transactions highlight the reliance on investment banking relationships for capital structure management, which is a prerequisite for future commercialization partnerships.

SELLAS Life Sciences Group, Inc. (SLS) - Canvas Business Model: Key Activities

You're looking at the core engine driving SELLAS Life Sciences Group, Inc. right now-the actual work being done to move their pipeline candidates toward potential approval and market entry. This is where the capital raised is being deployed.

Executing final analysis of Phase 3 REGAL trial for GPS (anticipated by year-end 2025)

The primary focus for Galinpepimut-S (GPS) is the conclusion of the Phase 3 REGAL trial in Acute Myeloid Leukemia (AML) patients in the second complete remission (CR2) setting. The final analysis is event-driven, set to occur upon reaching 80 events (deaths).

Key milestones related to this activity include:

• Enrollment completion for REGAL trial in April 2024.
• Independent Data Monitoring Committee (IDMC) recommended continuation without modification in January 2025, following an interim analysis at 60 events.
• Historical Phase 2 data for GPS showed a median Overall Survival (OS) of 21.0 months compared to 5.4 months with best standard care.

Advancing SLS009 clinical development, planning 80-patient first-line AML trial (Q1 2026)

SELLAS Life Sciences Group, Inc. is actively preparing the next step for SLS009, the selective CDK9 inhibitor, following positive Phase 2 data in relapsed/refractory (r/r) AML. The FDA recommended advancing into a first-line study, which is planned as an 80-patient randomized trial, with enrollment expected to start by Q1 2026.

The Phase 2 results provided strong justification for this advancement:

Research and development (R&D) of novel cancer immunotherapeutics and inhibitors

The ongoing R&D activities are reflected in the quarterly spending, showing a commitment to pipeline advancement across multiple indications, including preclinical work presented at the European Society for Medical Oncology (ESMO) Congress in October 2025.

Here's a look at the recent R&D financial commitment:

• Research and development Expenses for the quarter ended September 30, 2025: $4.2 million.
• Research and development Expenses for the first half of 2025: $7.1 million.

Securing non-dilutive grant funding for pipeline expansion

SELLAS Life Sciences Group, Inc. has actively pursued non-dilutive capital to support pipeline expansion, specifically for the SLS009 development into the frontline setting in AML, as noted in early 2025 objectives. The company also bolstered its cash position through equity financing activities in the latter half of 2025.

Financial inflows supporting operations:

Regulatory filings and interactions with FDA and EMA for product candidates

Regulatory interactions are key to defining the path to market for both GPS and SLS009. The company has secured several important designations recognizing the potential of its assets in rare and pediatric populations.

Regulatory designations secured:

• FDA Fast Track Designation for SLS009 in r/r AML and r/r PTCL.
• EMA Orphan Drug Designation (ODD) for SLS009 in AML and peripheral T-cell lymphoma (PTCL).
• FDA Rare Pediatric Disease Designation (RPDD) for GPS for pediatric AML.
• FDA RPDD for SLS009 for pediatric ALL and pediatric AML (granted July 2024).

The FDA provided guidance to advance SLS009 into the first-line AML trial, indicating a preference for response rate as the primary endpoint for that study, which may support a New Drug Application (NDA).

SELLAS Life Sciences Group, Inc. (SLS) - Canvas Business Model: Key Resources

The Key Resources for SELLAS Life Sciences Group, Inc. as of late 2025 are centered on its clinical pipeline, financial stability derived from recent financing activities, and the underlying intellectual property and human capital driving development.

The financial foundation is supported by recent capital raises. As of September 30, 2025, SELLAS Life Sciences Group, Inc. reported cash and cash equivalents of approximately $44.3 million. This was subsequently bolstered by approximately $54.6 million in gross proceeds from warrant exercises completed across September and October 2025, with net proceeds of $29.1 million received in October 2025 alone.

The core of the company's value resides in its two primary clinical assets, which are supported by a portfolio of intellectual property and regulatory advantages.

• Lead product candidate: Galinpepimut-S (GPS) immunotherapeutic targeting WT1 protein.
• Selective CDK9 inhibitor: SLS009 (tambiciclib).
• Intellectual property (IP) portfolio and regulatory designations (e.g., Fast Track, RPDD).
• Specialized scientific and clinical development personnel.

The pipeline assets have secured important regulatory milestones, which provide potential market exclusivity and development acceleration pathways.

The intellectual property supporting GPS, exclusively licensed from Memorial Sloan Kettering Cancer Center, includes patent exclusivity on component peptides extending to at least 2033 in the U.S.. The personnel resource includes the President and Chief Executive Officer, Angelos Stergiou, MD, ScD h.c., and key investigators in ongoing trials.

Further detail on the clinical momentum supporting these resources includes:

• GPS Phase 3 REGAL trial received a positive Independent Data Monitoring Committee recommendation to continue without modification.
• SLS009 Phase 2 data accepted for presentation at the ASH 2025 Annual Meeting.
• Planned initiation of a randomized 80-patient trial for SLS009 in newly diagnosed, first-line AML patients expected in Q1 2026.

SELLAS Life Sciences Group, Inc. (SLS) - Canvas Business Model: Value Propositions

You're looking at the core value SELLAS Life Sciences Group, Inc. (SLS) offers to its target customer segments, which are primarily patients with high-unmet-need hematologic malignancies. The value is entirely driven by the clinical potential of its pipeline assets, GPS and SLS009, as of late 2025.

For the lead candidate, SLS009 (tambiciclib), a highly selective CDK9 inhibitor, the value proposition in relapsed/refractory (r/r) Acute Myeloid Leukemia (AML) patients who have failed venetoclax-based regimens is starkly defined by survival improvement over historical standards.

• Potential to nearly triple median overall survival (mOS) compared to historical benchmarks.
• Demonstrated high response rates across genetically defined, high-risk subgroups.

Here's the quick math on the Phase 2 trial results for SLS009 in r/r AML patients who have received prior venetoclax therapy:

The differentiation for SLS009 is its mechanism, targeting CDK9, which appears to overcome resistance mechanisms, including those related to TP53 mutations. Preclinical data in TP53-mutated AML showed up to a 97% reduction in leukemia cells with combination therapy, and 80% as monotherapy.

The value proposition also extends to specific high-risk mutations seen in the Phase 2 trial:

• ASXL1 mutation ORR: 67% (4/6 patients).
• RUNX1 mutation ORR: 60% (3/5 patients).
• TP53 mutation ORR: 33% (1/3 patients).

For the lead candidate, GPS, the value proposition centers on its novel mechanism targeting the WT1 protein, which is present in an array of tumor types, addressing a broad spectrum of hematologic malignancies and solid tumors. The Phase 3 REGAL trial for GPS is event-driven, with a final analysis anticipated by year-end 2025.

Furthermore, SELLAS Life Sciences Group, Inc. (SLS) is creating value by demonstrating the broad applicability of its pipeline. Preclinical data for SLS009 in T-cell prolymphocytic leukemia (T-PLL) showed a statistically significant survival benefit over venetoclax alone in an in vivo model. Specifically, SLS009 monotherapy prolonged survival to 7.4 weeks compared to venetoclax alone at 4.4 weeks (p<0.05), and the combination extended it to 7.9 weeks.

This clinical progress is supported by a strengthening balance sheet, which underpins the ability to deliver on these value propositions. As of September 30, 2025, SELLAS Life Sciences Group, Inc. (SLS) reported $44.3 million in cash and cash equivalents. The company also secured $29.1 million in net proceeds in October 2025 from warrant exercises, following $54.6 million in gross proceeds from warrant exercises in September and October 2025.

Operating expenses reflect the development stage: the Research and development expenses for the third quarter of 2025 were $4.2 million, contributing to a net loss of $6.8 million for the quarter.

SELLAS Life Sciences Group, Inc. (SLS) - Canvas Business Model: Customer Relationships

You're managing relationships in a clinical-stage biotech, so every interaction with an investigator or investor is about data milestones. Here is how SELLAS Life Sciences Group, Inc. (SLS) structures its key customer relationships as of late 2025.

High-touch engagement with clinical investigators and oncologists

Engagement centers on the two lead assets: the Phase 3 REGAL trial for GPS and the ongoing Phase 2 study for SLS009. Key Opinion Leaders (KOLs) are central to this, providing guidance and driving trial participation. For instance, Dr. Panagiotis Tsirigotis, a KOL, is noted as having enrolled the highest number of patients in the Phase 3 REGAL trial. Dr. Sharif Khan serves as an investigator in both the GPS REGAL trial and the SLS009 clinical program. The Scientific Advisory Board (SAB) was recently expanded in June 2025 with experts like Dr. Philip C. Amrein and Dr. Alex Kentsis to provide strategic guidance as the company approaches key inflection points. The company's R&D Day on October 29, 2025, featured several medical experts discussing the AML landscape, including Dr. Omer Jamy and Dr. Panagiotis Tsirigotis.

The scale of this engagement is tied directly to the clinical pipeline:

• Phase 3 REGAL trial final analysis anticipated upon occurrence of 80 deaths.
• Phase 2 SLS009 trial in r/r AML with MDS-related changes.
• Preclinical data for SLS009 in colorectal cancer presented at ASCO 2025 (Abstract #: 3121).

Direct communication with institutional investors via R&D Days and updates

SELLAS Life Sciences Group, Inc. uses focused events to communicate directly with the financial community. The virtual R&D Day on Wednesday, October 29, 2025, at 10:00 AM ET was a primary vehicle for this, featuring KOLs and management discussing the unmet medical need in AML. This event provided an overview of the ongoing Phase 3 REGAL trial and an update on the SLS009 program, highlighting recently reported Phase 2 data. Following this, the company conducted 1x1 meetings with investors on Wednesday, November 12th. The company's financial health is a key topic for these discussions, as evidenced by its reported Current Ratio of 4.91 as of the October 29 announcement, though the company is noted as not yet profitable.

Patient advocacy group outreach for clinical trial enrollment and support

While specific metrics on patient advocacy group engagement are not detailed, the focus on advancing late-stage trials like the Phase 3 REGAL trial for GPS and the Phase 2 study for SLS009 necessitates strong relationships with patient groups to support clinical trial enrollment and patient support infrastructure. The company is targeting difficult-to-treat cancers, which often requires close collaboration with organizations representing those patient populations to ensure trial access and understanding.

Investor relations managing expectations around event-driven trial readouts

Investor relations is heavily event-driven, focusing on managing expectations around critical clinical data readouts. The company provided updates on these events through various channels:

Insider activity shows confidence, with insiders buying $100.8K worth of shares in the last 3 months ending November 18, 2025.

Scientific publications and conference presentations (e.g., ASH 2025)

Scientific validation through peer-reviewed presentation is a core relationship driver with the scientific community. SELLAS Life Sciences Group, Inc. had a busy second half of 2025:

• ASH 2025 (December 6 - 9, 2025): Presentation of Phase 2 SLS009 data in r/r AML with MDS-related changes.
• ESMO Congress 2025 (October 17-21, 2025): Presentation of in vivo preclinical data for SLS009 in T-Cell Prolymphocytic Leukemia (T-PLL).
• ASCO 2025 (May 30-June 3, 2025): Poster presentation of preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer cell lines (Poster Board #: 436).

The preclinical abstract for the ASH presentation was published on the ASH Annual Meeting website and in Blood, providing scientific grounding for the clinical data being presented. Research and development expenses for the first half of 2025 were $7.1 million.

SELLAS Life Sciences Group, Inc. (SLS) - Canvas Business Model: Channels

You're looking at how SELLAS Life Sciences Group, Inc. gets its science and its capital out into the world. For a late-stage biopharma company, the channels are less about retail shelves and more about clinical centers, scientific forums, and the capital markets. Here's the breakdown of the key conduits for SELLAS Life Sciences Group, Inc. as of late 2025.

Global network of clinical trial sites (U.S. and Europe) for drug delivery

The primary channel for delivering the value proposition-novel cancer therapies-is through the execution of its clinical trials. The Phase 3 REGAL trial for galinpepimut-S (GPS) is a global effort. We see direct evidence of this network in the key investigators mentioned. For instance, the University of Alabama (UAB) in the U.S. serves as one of the trial's highest enrolling sites, with Dr. Omer Jamy as the principal investigator. On the European side, Dr. Panagiotis Tsirigotis at the National and Kapodistrian University of Athens, Greece, is noted for enrolling the highest number of patients, confirming active European site engagement. The company is also preparing an 80-patient trial for newly diagnosed AML patients, expected to begin enrollment in the first quarter of 2026, which will require activating additional sites across its network.

Scientific and medical conferences (ASH, ESMO) for data dissemination

Disseminating clinical and preclinical data is crucial for validation and future partnership or commercialization. SELLAS Life Sciences Group, Inc. actively uses major medical congresses as a primary channel for this. The positive Phase 2 data for SLS009 in relapsed/refractory (r/r) AML were accepted for presentation at the American Society of Hematology (ASH) Annual Meeting in December 2025. Furthermore, preclinical data on SLS009 in T-cell prolymphocytic leukemia (T-PLL) were presented at the European Society for Medical Oncology (ESMO) Congress in October 2025 in Berlin, Germany. Internally, the company used a Virtual R&D Day on October 29, 2025, to review these programs with key opinion leaders.

Regulatory submission pathways (e.g., BLA/NDA) to FDA and EMA

The regulatory bodies-the FDA and EMA-are the ultimate gatekeepers, making the submission pathway a critical channel. The final analysis for the Phase 3 REGAL trial is event-driven, anticipated by year-end 2025 once 80 deaths are reached. Based on projections, the BLA submission to the FDA was targeted for October-November 2025, following the final analysis and data lock. For SLS009, the company has already secured significant designations, including FDA Rare Pediatric Disease Designation for pediatric AML and pediatric ALL, and EMA orphan drug designation for AML and peripheral T-cell lymphoma. The FDA also provided feedback in Q2 2025, recommending the next SLS009 trial be an 80-patient study in first-line AML patients.

Direct investor relations and corporate communications for capital raising

Keeping the capital flowing is a constant channel activity. SELLAS Life Sciences Group, Inc. successfully executed significant financing events in 2025. They announced a $25 million registered direct offering in January 2025. More recently, the company received approximately $54.6 million in gross proceeds from warrant exercises in September and October 2025. As of September 30, 2025, the cash and cash equivalents position stood at $44.3 million, bolstered by an additional $29.1 million in net proceeds received in October 2025 from those warrant exercises. The CEO was scheduled for direct investor meetings on November 12, 2025, showing active engagement with the financial community.

Here's a quick look at the recent capital activity as of late 2025:

Academic collaborations for preclinical and translational research

The foundation of the pipeline relies on strong academic ties, which act as a channel for early-stage discovery and validation. The lead product candidate, GPS, is explicitly licensed from Memorial Sloan Kettering Cancer Center. This licensing agreement is a key channel for bringing foundational science into the company's development pipeline. The company also noted that preclinical data for SLS009 were presented at ESMO 2025, which stems from translational research efforts. Furthermore, the company is developing pediatric programs for hematological malignancies, which often involves collaboration with specialized academic pediatric centers.

• GPS licensed from Memorial Sloan Kettering Cancer Center.
• Preclinical data for SLS009 presented at ESMO 2025.
• FDA recommended a new trial for SLS009 in first-line AML, with enrollment planned for Q1 2026.
• SLS009 received FDA Rare Pediatric Disease Designation.

SELLAS Life Sciences Group, Inc. (SLS) - Canvas Business Model: Customer Segments

You're looking at the core patient populations SELLAS Life Sciences Group, Inc. is targeting with its late-stage assets, GPS and SLS009, as of late $\text{2025}$. This is where the clinical data translates directly into market opportunity.

The primary focus is on Acute Myeloid Leukemia ($\text{AML}$), a disease with an estimated $\text{22,010}$ new diagnoses in the $\text{US}$ for $\text{2025}$. $\text{AML}$ represents about $\text{1}$ out of $\text{3}$ leukemias in adults.

Acute Myeloid Leukemia (AML) patients in complete remission (CR2)

This segment is the target for the Galinpepimut-S ($\text{GPS}$) Phase 3 $\text{REGAL}$ trial, which is event-driven with a final analysis anticipated by year-end $\text{2025}$ once $\text{80}$ deaths are reached.

• The $\text{REGAL}$ trial involves $\text{126}$ patients achieving $\text{CR2}$ (second complete remission).
• Phase 2 data for $\text{GPS}$ in $\text{CR2}$ patients showed a median survival of $\text{21}$ months versus $\text{5.4}$ months for the comparator, with a $\text{p-value}$ of $\text{0.02}$.

Relapsed/refractory (r/r) AML patients, especially venetoclax-resistant

This segment is the focus for the $\text{SLS009}$ program, which has shown efficacy in patients who have failed prior standard-of-care regimens, including those resistant to venetoclax-based therapy.

The Overall Response Rate ($\text{ORR}$) for $\text{SLS009}$ in this population was also encouraging:

• $\text{ORR}$ of $\text{33}\%$ in all patients ($\text{n=54}$).
• $\text{ORR}$ of $\text{44}\%$ in $\text{AML-MR}$ patients.
• $\text{ORR}$ of $\text{50}\%$ in $\text{AML-MR}$ with Myelomonocytic/Myelomonoblastic ($\text{M4/M5}$) subtype.

Oncologists and hematologists specializing in blood cancers

These are the treating physicians who prescribe $\text{GPS}$ and $\text{SLS009}$. Their segment is defined by the patient populations they serve, which include the $\text{22,010}$ estimated new $\text{AML}$ cases in $\text{2025}$, with the average patient age being about $\text{69}$ years.

Potential large pharmaceutical/biotech companies for commercial licensing

These entities represent potential strategic partners or acquirers, incentivized by regulatory advantages tied to $\text{SLS}$'s pipeline assets.

• $\text{FDA}$ Rare Pediatric Disease Designation ($\text{RPDD}$) for $\text{GPS}$ in pediatric $\text{AML}$ makes $\text{SLS}$ eligible for a Priority Review Voucher ($\text{PRV}$) upon approval.
• Recent sales valuations for $\text{PRV}$s have been around $\text{\$100}$ million.
• $\text{SLS}$ reported $\text{\$44.3}$ million in cash and cash equivalents as of September $\text{30, 2025}$, supplemented by $\text{\$29.1}$ million in net proceeds from warrant exercises in October $\text{2025}$.

Pediatric AML and ALL patient populations (via RPDD designations)

Both $\text{GPS}$ and $\text{SLS009}$ have secured $\text{RPDD}$ from the $\text{FDA}$ for pediatric $\text{AML}$. $\text{SLS009}$ also holds $\text{RPDD}$ for pediatric $\text{ALL}$.

• The $\text{RPDD}$ for $\text{SLS009}$ in pediatric $\text{AML}$ supports an $\text{80}$-patient trial planned to begin in $\text{Q1 2026}$.
• The designation is for serious or life-threatening diseases affecting fewer than $\text{200,000}$ people in the $\text{US}$, primarily individuals under $\text{18}$.

SELLAS Life Sciences Group, Inc. (SLS) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for SELLAS Life Sciences Group, Inc. as of late 2025. For a late-stage clinical company, the cost structure is heavily weighted toward research and development, which is where the bulk of your capital goes before a product is commercialized.

Here's a quick look at the primary operating expenses reported for the third quarter ending September 30, 2025:

The R&D spend is definitely the dominant cost driver, as you'd expect. It's important to note that the R&D expense for the nine months ending September 30, 2025, at $11.3 million, was down from $14.7 million for the same period in 2024. That reduction points directly to specific activities winding down.

The decrease in R&D spend year-over-year was primarily driven by lower costs associated with the clinical programs. Here are the key components that make up that R&D expenditure:

• Clinical trial execution and monitoring costs for the REGAL Phase 3 trial.
• Decreased clinical trial expenses for the SLS009 program.
• Lower manufacturing costs and clinical drug supply purchases.
• Reduced clinical and regulatory consulting costs.

For G&A, the Q3 2025 figure of $2.87 million compared to $3.0 million in Q3 2024. That slight dip was mainly due to lower professional fees, though it was partially offset by higher personnel-related expenses, including non-cash stock-based compensation.

Finally, you have the costs tied to your core assets. The lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center (MSKCC). While specific ongoing licensing fees aren't broken out in the main expense lines, the initial licensing agreement is a fixed part of the cost structure that supports the development of GPS.

SELLAS Life Sciences Group, Inc. (SLS) - Canvas Business Model: Revenue Streams

You're looking at the financial engine of SELLAS Life Sciences Group, Inc. as of late 2025. For a late-stage clinical biotech like SELLAS Life Sciences Group, Inc., the revenue stream isn't about selling pills yet; it's about funding the journey to get there. Right now, the books reflect this reality.

Currently no product revenue; typical for a late-stage clinical biotech. As of the second quarter of 2025, SELLAS Life Sciences Group, Inc. reported $0.0 in revenue, which is exactly what you'd expect when the focus is entirely on advancing clinical trials for novel cancer therapies like GPS and SLS009, not commercial sales. This lack of sales revenue is the cost of doing late-stage development.

The immediate, tangible revenue stream comes from financing the pipeline. SELLAS Life Sciences Group, Inc. successfully tapped investor commitment through warrant exercises in the recent past. This is crucial cash flow to keep the lights on and the trials running.

Here's a breakdown of the capital infusion from warrant exercises in late 2025:

This total of $54.6 million in gross proceeds from warrant exercises in September and October 2025 provided significant liquidity. For context, the company reported $44.3 million in cash and cash equivalents as of September 30, 2025, with an additional $29.1 million in net proceeds received in October 2025 from these exercises.

Beyond the current financing activities, the future revenue potential is tied directly to clinical success and strategic deal-making. These are the expected, but not yet realized, revenue sources:

• Potential future milestone payments from commercialization partnerships.
• Potential future product sales or licensing royalties post-regulatory approval.

The company is actively working to secure non-dilutive funding, which is essentially grant money that doesn't require giving up equity or future royalties. This is a key strategic move to offset cash burn.

• Non-dilutive grant funding for specific development programs (applied for). SELLAS Life Sciences Group, Inc. applied for such funding to expand SLS009 development into the frontline setting in Acute Myeloid Leukemia (AML).

Finance: draft 13-week cash view by Friday.